FDA shall revise
the guidance to display the OMB control number, expiration date and
the burden statement.
Inventory as of this Action
This guidance discusses how the agency
will implement a pilot program for frequent scientific feedback and
interactions between FDA and applicants during the investigational
phase of certain Fast Track drug and biological products.
Applicants are being asked to apply to participate in the Pilot